1. Home
  2. KROS vs PML Comparison

KROS vs PML Comparison

Compare KROS & PML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KROS
  • PML
  • Stock Information
  • Founded
  • KROS 2015
  • PML 2002
  • Country
  • KROS United States
  • PML United States
  • Employees
  • KROS N/A
  • PML N/A
  • Industry
  • KROS Biotechnology: Pharmaceutical Preparations
  • PML Investment Managers
  • Sector
  • KROS Health Care
  • PML Finance
  • Exchange
  • KROS Nasdaq
  • PML Nasdaq
  • Market Cap
  • KROS 565.0M
  • PML 478.0M
  • IPO Year
  • KROS 2020
  • PML N/A
  • Fundamental
  • Price
  • KROS $16.01
  • PML $7.74
  • Analyst Decision
  • KROS Buy
  • PML
  • Analyst Count
  • KROS 14
  • PML 0
  • Target Price
  • KROS $20.56
  • PML N/A
  • AVG Volume (30 Days)
  • KROS 412.4K
  • PML 188.0K
  • Earning Date
  • KROS 11-05-2025
  • PML 01-01-0001
  • Dividend Yield
  • KROS N/A
  • PML 5.65%
  • EPS Growth
  • KROS N/A
  • PML N/A
  • EPS
  • KROS 0.47
  • PML N/A
  • Revenue
  • KROS $232,844,000.00
  • PML N/A
  • Revenue This Year
  • KROS $5,998.31
  • PML N/A
  • Revenue Next Year
  • KROS N/A
  • PML N/A
  • P/E Ratio
  • KROS $33.74
  • PML N/A
  • Revenue Growth
  • KROS 85820.30
  • PML N/A
  • 52 Week Low
  • KROS $9.12
  • PML $6.92
  • 52 Week High
  • KROS $72.37
  • PML $9.46
  • Technical
  • Relative Strength Index (RSI)
  • KROS 62.29
  • PML 77.48
  • Support Level
  • KROS $15.34
  • PML $7.46
  • Resistance Level
  • KROS $16.11
  • PML $7.86
  • Average True Range (ATR)
  • KROS 0.44
  • PML 0.08
  • MACD
  • KROS -0.01
  • PML 0.05
  • Stochastic Oscillator
  • KROS 91.59
  • PML 82.35

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

About PML Pimco Municipal Income Fund II of Beneficial Interest

PIMCO Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as education, healthcare, and others.

Share on Social Networks: